ReviewHuman vaccines & immunotherapeutics2016
Tick-borne encephalitis: What travelers should know when visiting an endemic country.
Review in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-centre, randomized controlled pilot trial.Journal of travel medicine · 2024Trial
- Travel vaccination in senior travelers: current evidence, challenges, and prevention.Tropical diseases, travel medicine and vaccines · 2026Review
- Two Coding-Complete Genomes of Tick-Borne Encephalitis Virus Sequenced fromPathogens (Basel, Switzerland) · 2026Article
- Human T Cell Responses to Flavivirus Vaccines.European journal of immunology · 2025Review
- An autochthonous case of severeIDCases · 2025Article
- Flaviviruses-Induced Neurological Sequelae.Pathogens (Basel, Switzerland) · 2024Review
- The structure of immature tick-borne encephalitis virus supports the collapse model of flavivirus maturation.Science advances · 2024Article
- Severe Tick-Borne Encephalitis (TBE) in a Patient with X-Linked Agammaglobulinemia; Treatment with TBE Virus IgG Positive Plasma, Clinical Outcome and T Cell Responses.Journal of clinical immunology · 2024Article
- Article
- Tick-Borne Encephalitis (TBE): From Tick to Pathology.Journal of clinical medicine · 2023Review
- Fatal Case of Imported Tick-Borne Encephalitis in South Serbia.Tropical medicine and infectious disease · 2022Article
- Article
- Enteric Ganglioneuritis, a Common Feature in a Subcutaneous TBEV Murine Infection Model.Microorganisms · 2021Article
- Tick-Borne Encephalitis Virus Seropositivity among Tick Infested Individuals in Serbia.Pathogens (Basel, Switzerland) · 2021Article
- Vaccines and Senior Travellers.Frontiers in aging · 2021Review
- Remdesivir triphosphate can efficiently inhibit the RNA-dependent RNA polymerase from various flaviviruses.Antiviral research · 2020Article
- Article
- Review
- Perceptions of tick-borne encephalitis risk: a survey of travellers and travel clinics from Canada, Germany, Sweden and the UK.Journal of travel medicine · 2019Article
- Multinational survey shows low awareness of tick-borne encephalitis and rabies among travellers to endemic regions.Journal of travel medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tick-borne encephalitis (TBE) is an acute febrile illness with neurological manifestations that is prevalent in forested areas of moderate climate in Europe and Asia. TBE virus is transmitted by ticks and rarely by unpasteurized milk and dairy products. The disease burden is attributed mainly to resulting long-term disability, especially in individuals over 50 y of age. Currently, there is no causative treatment, but a very effective vaccination is available with a good safety profile. The vaccination requires 3 basic doses to be fully effective and regular boosters afterwards. An accelerated vaccination schedule enables a patient to reach reasonably protective titres within 3 to 4 weeks from the first injection. The risk of travel-related TBE is estimated to be less than the risk of acquiring typhoid fever while visiting highly endemic regions in South Asia, but more than the risk of acquiring Japanese encephalitis, meningococcal invasive disease, or rabies. The pre-travel risk assessment of acquiring TBE should consider known risk factors which include 1) the country and regions to be visited; 2) April to November season; 3) altitude less than 1500 m above the sea level; 4) duration of stay; 5) the extent of tick-exposure associated activities including leisure and professional outdoor activities within the endemic area; and 6) age and comorbidities of the traveler. A major challenge, however, is the very low awareness of the risk of contracting TBE in those who travel to industrialized European countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.